Cargando…

Exhaled breath 8-isoprostane as a marker of asthma severity

INTRODUCTION: Oxidative stress is a non-specific feature of airway inflammation in asthmatics. 8-Isoprostane (8-IP), a prostaglandin-F(2α) isomer, is a relatively new marker of oxidative stress and may be measured in exhaled breath condensate (EBC) of patients with asthma. This research study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Piotrowski, Wojciech J., Majewski, Sebastian, Marczak, Jerzy, Kurmanowska, Zofia, Górski, Paweł, Antczak, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400897/
https://www.ncbi.nlm.nih.gov/pubmed/22852009
http://dx.doi.org/10.5114/aoms.2012.28639
_version_ 1782238542428110848
author Piotrowski, Wojciech J.
Majewski, Sebastian
Marczak, Jerzy
Kurmanowska, Zofia
Górski, Paweł
Antczak, Adam
author_facet Piotrowski, Wojciech J.
Majewski, Sebastian
Marczak, Jerzy
Kurmanowska, Zofia
Górski, Paweł
Antczak, Adam
author_sort Piotrowski, Wojciech J.
collection PubMed
description INTRODUCTION: Oxidative stress is a non-specific feature of airway inflammation in asthmatics. 8-Isoprostane (8-IP), a prostaglandin-F(2α) isomer, is a relatively new marker of oxidative stress and may be measured in exhaled breath condensate (EBC) of patients with asthma. This research study aimed to evaluate the usefulness of EBC 8-IP as a marker of severity and control of severe adult asthma. MATERIAL AND METHODS: Twenty-seven severe, never-smoking asthmatics were studied. According to positive or negative reversibility testing, this group was subdivided into reversible and irreversible asthma groups. All participants were observed for 8 weeks during which they completed daily diary observations including day and night symptoms, number of awakenings, peak expiratory flow (PEF) variability, daily rescue medication usage and oral steroids consumption. They attended the clinic 3 times and on these occasions spirometry assessments, EBC collection and asthma control tests (ACT) were done. Two control groups were included: 11 healthy never-smokers and 16 newly diagnosed and never-treated, non-smoking mild asthmatics. RESULTS: There were no statistically significant differences between severe asthma and healthy control or never-treated asthma groups in concentrations of EBC 8-IP (median and interquartile range: 4.67; 2.50-27.92 vs. 6.93; 2.5-12.98 vs. 3.80; 2.50-10.73, respectively). No correlations were found between EBC 8-IP and asthma control parameters, such as ACT results, night and day symptoms, consumption of rescue medication, percentage of days free of oral steroids, PEF diurnal variation, lung function test results, forced expiratory volume in the 1 s reversibility, and markers of systemic inflammation. CONCLUSIONS: Our study results suggest that EBC 8-IP measurements are not useful for asthma monitoring.
format Online
Article
Text
id pubmed-3400897
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-34008972012-07-31 Exhaled breath 8-isoprostane as a marker of asthma severity Piotrowski, Wojciech J. Majewski, Sebastian Marczak, Jerzy Kurmanowska, Zofia Górski, Paweł Antczak, Adam Arch Med Sci Clinical Research INTRODUCTION: Oxidative stress is a non-specific feature of airway inflammation in asthmatics. 8-Isoprostane (8-IP), a prostaglandin-F(2α) isomer, is a relatively new marker of oxidative stress and may be measured in exhaled breath condensate (EBC) of patients with asthma. This research study aimed to evaluate the usefulness of EBC 8-IP as a marker of severity and control of severe adult asthma. MATERIAL AND METHODS: Twenty-seven severe, never-smoking asthmatics were studied. According to positive or negative reversibility testing, this group was subdivided into reversible and irreversible asthma groups. All participants were observed for 8 weeks during which they completed daily diary observations including day and night symptoms, number of awakenings, peak expiratory flow (PEF) variability, daily rescue medication usage and oral steroids consumption. They attended the clinic 3 times and on these occasions spirometry assessments, EBC collection and asthma control tests (ACT) were done. Two control groups were included: 11 healthy never-smokers and 16 newly diagnosed and never-treated, non-smoking mild asthmatics. RESULTS: There were no statistically significant differences between severe asthma and healthy control or never-treated asthma groups in concentrations of EBC 8-IP (median and interquartile range: 4.67; 2.50-27.92 vs. 6.93; 2.5-12.98 vs. 3.80; 2.50-10.73, respectively). No correlations were found between EBC 8-IP and asthma control parameters, such as ACT results, night and day symptoms, consumption of rescue medication, percentage of days free of oral steroids, PEF diurnal variation, lung function test results, forced expiratory volume in the 1 s reversibility, and markers of systemic inflammation. CONCLUSIONS: Our study results suggest that EBC 8-IP measurements are not useful for asthma monitoring. Termedia Publishing House 2012-07-04 2012-07-04 /pmc/articles/PMC3400897/ /pubmed/22852009 http://dx.doi.org/10.5114/aoms.2012.28639 Text en Copyright © 2012 Termedia & Banach http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Research
Piotrowski, Wojciech J.
Majewski, Sebastian
Marczak, Jerzy
Kurmanowska, Zofia
Górski, Paweł
Antczak, Adam
Exhaled breath 8-isoprostane as a marker of asthma severity
title Exhaled breath 8-isoprostane as a marker of asthma severity
title_full Exhaled breath 8-isoprostane as a marker of asthma severity
title_fullStr Exhaled breath 8-isoprostane as a marker of asthma severity
title_full_unstemmed Exhaled breath 8-isoprostane as a marker of asthma severity
title_short Exhaled breath 8-isoprostane as a marker of asthma severity
title_sort exhaled breath 8-isoprostane as a marker of asthma severity
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400897/
https://www.ncbi.nlm.nih.gov/pubmed/22852009
http://dx.doi.org/10.5114/aoms.2012.28639
work_keys_str_mv AT piotrowskiwojciechj exhaledbreath8isoprostaneasamarkerofasthmaseverity
AT majewskisebastian exhaledbreath8isoprostaneasamarkerofasthmaseverity
AT marczakjerzy exhaledbreath8isoprostaneasamarkerofasthmaseverity
AT kurmanowskazofia exhaledbreath8isoprostaneasamarkerofasthmaseverity
AT gorskipaweł exhaledbreath8isoprostaneasamarkerofasthmaseverity
AT antczakadam exhaledbreath8isoprostaneasamarkerofasthmaseverity